Pfizer Inc. PFE
i
Market dataready · fetched 2026-11-06T20:55:01.217Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T20:54:59.515976268Z
FundamentalsSEC EDGAR · ready · as of 2026-09-27 · fetched 2026-11-06T20:55:00.619686+00:00
Pfizer Inc. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 30.30 | 26.7% | 3.8% | 28.36 | 28.8% | 3.7% |
| 25Δ | 30.07 | 25.8% | 3.1% | 28.57 | 28.4% | 3.1% |
| 30Δ | 29.90 | 25.7% | 2.7% | 28.75 | 27.2% | 2.6% |
| 35Δ | 29.76 | 26.0% | 2.4% | 28.93 | 26.1% | 2.2% |
| 40Δ | 29.62 | 26.3% | 2.1% | 29.08 | 25.9% | 1.8% |
| 45Δ | 29.48 | 26.6% | 1.8% | 29.22 | 26.4% | 1.6% |
| 50Δ | 29.34 | 27.0% | 1.6% | 29.35 | 26.8% | 1.4% |
| 55Δ | 29.20 | 27.3% | 1.4% | 29.49 | 27.3% | 1.2% |
| 60Δ | 29.06 | 27.7% | 1.2% | 29.64 | 27.3% | 1.0% |
| 65Δ | 28.92 | 27.6% | 1.0% | 29.79 | 27.2% | 0.8% |
| 70Δ | 28.77 | 27.1% | 0.8% | 29.94 | 27.2% | 0.7% |
| 75Δ | 28.62 | 26.6% | 0.6% | 30.17 | 28.9% | 0.5% |
| 80Δ | 28.45 | 26.4% | 0.5% | |||
20Δ
- Pseudo strike
- 30.30
- IV
- 26.7%
- B/E move
- 3.8%
- Pseudo strike
- 28.36
- IV
- 28.8%
- B/E move
- 3.7%
25Δ
- Pseudo strike
- 30.07
- IV
- 25.8%
- B/E move
- 3.1%
- Pseudo strike
- 28.57
- IV
- 28.4%
- B/E move
- 3.1%
30Δ
- Pseudo strike
- 29.90
- IV
- 25.7%
- B/E move
- 2.7%
- Pseudo strike
- 28.75
- IV
- 27.2%
- B/E move
- 2.6%
35Δ
- Pseudo strike
- 29.76
- IV
- 26.0%
- B/E move
- 2.4%
- Pseudo strike
- 28.93
- IV
- 26.1%
- B/E move
- 2.2%
40Δ
- Pseudo strike
- 29.62
- IV
- 26.3%
- B/E move
- 2.1%
- Pseudo strike
- 29.08
- IV
- 25.9%
- B/E move
- 1.8%
45Δ
- Pseudo strike
- 29.48
- IV
- 26.6%
- B/E move
- 1.8%
- Pseudo strike
- 29.22
- IV
- 26.4%
- B/E move
- 1.6%
50Δ
- Pseudo strike
- 29.34
- IV
- 27.0%
- B/E move
- 1.6%
- Pseudo strike
- 29.35
- IV
- 26.8%
- B/E move
- 1.4%
55Δ
- Pseudo strike
- 29.20
- IV
- 27.3%
- B/E move
- 1.4%
- Pseudo strike
- 29.49
- IV
- 27.3%
- B/E move
- 1.2%
60Δ
- Pseudo strike
- 29.06
- IV
- 27.7%
- B/E move
- 1.2%
- Pseudo strike
- 29.64
- IV
- 27.3%
- B/E move
- 1.0%
65Δ
- Pseudo strike
- 28.92
- IV
- 27.6%
- B/E move
- 1.0%
- Pseudo strike
- 29.79
- IV
- 27.2%
- B/E move
- 0.8%
70Δ
- Pseudo strike
- 28.77
- IV
- 27.1%
- B/E move
- 0.8%
- Pseudo strike
- 29.94
- IV
- 27.2%
- B/E move
- 0.7%
75Δ
- Pseudo strike
- 28.62
- IV
- 26.6%
- B/E move
- 0.6%
- Pseudo strike
- 30.17
- IV
- 28.9%
- B/E move
- 0.5%
80Δ
- Pseudo strike
- 28.45
- IV
- 26.4%
- B/E move
- 0.5%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 23.00% | |
| 19.69% | |
| 29.54% | |
| 17.54% | |
| 20.19% | |
| 20.28% | |
| 24.83% | |
| 21.69% | |
| 21.24% | |
| 23.31% | |
| 22.55% | |
| 21.55% | |
| 19.84% | |
| 23.13% | |
| 22.91% | |
| 22.48% | |
| 22.42% | |
| 20.59% | |
| 22.57% | |
| 23.24% | |
| 20.66% | |
| 22.08% | |
| 22.97% | |
| 21.86% | |
| 67.18% | |
| 19.36% | |
| 20.71% | |
| 21.56% | |
| 22.76% | |
| 23.03% | |
| 21.77% | |
| 22.53% | |
| 22.67% | |
| 22.79% | |
| 27.44% | |
| 20.93% | |
| 23.62% | |
| 22.51% | |
| 24.67% | |
| 22.90% | |
| 22.25% | |
| 25.55% | |
| 27.81% | |
| 32.74% | |
| 26.36% | |
| 27.41% | |
| 28.80% | |
| 26.92% | |
| 29.91% | |
| 27.92% | |
| 30.17% | |
| 30.38% | |
| 31.23% | |
| 32.61% | |
| 33.14% |
Drug Manufacturers - General
SNY
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The…
More →ABBV
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
More →AMGN
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular…
More →AMRN
Amarin Corporation plc, a pharmaceutical company, is engaged in the development and commercialization of therapies for the treatment of cardiovascular disease in the United…
More →AZN
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections,…
More →BIIB
Description unavailable
More →